KCNH2 antibody (Extracellular)

Catalog No. ABIN7043545

Product Details anti-KCNH2 Antibody

Target: KCNH2 (Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2 (KCNH2))

Binding Specificity: AA 430-445, Extracellular

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This KCNH2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (IF), Immunoprecipitation (IP), Immunochromatography (IC), Live Cell Imaging (LCI)

Purpose: A Rabbit Polyclonal Antibody to KV11.1 Channel

Specificity: Extracellular, between S1 and S2 domains.

Cross-Reactivity: Human, Rat

Predicted Reactivity: Rat,mouse - 11,16 amino acid residues identical, dog,rabbit - 15,16 amino residues identical

Characteristics: Anti-KCNH2 (HERG) (extracellular) Antibody (ABIN7043545, ABIN7045006 and ABIN7045007)) is a highly specific antibody directed against an extracellular epitope of the human KV11.1 channel. The antibody can be used in western blot, immunoprecipitation, immunohistochemical, immunocytochemical and indirect flow cytometry applications. It has been designed to recognize KV11.1 from human, rat, and mouse samples.

Purification: Affinity purified on immobilized antigen.

Immunogen:

Immunogen: Synthetic peptide

Immunogen Sequence: AFLLKETEEGPPATEC corresponding to residues 430-445 of human KV11.1 (HERG)

Isotype: IgG

Application Details

Application Notes:

Antigen preadsorption control: 1 μg peptide per 1 μg antibody

Application Dilutions Immunohistochemistry paraffin embedded sections ihc: N/A

Application Dilutions Western blot wb: 1:200

Comment:

Cited Application: IFC

Negative Control: BLP-PC109

Blocking Peptide: BLP-PC109

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Recosntitute with double distilled water (DDW) to a concentration of 1.0 mg/mL.

Concentration: 1 mg/mL

Buffer: PBS pH 7.4

Storage: 4 °C,-20 °C

Storage Comment:

Storage before reconstitution: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.

Storage after reconstitution: The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).

Target Details for KCNH2

Target: KCNH2 (Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2 (KCNH2))

Alternative Name: KCNH2 (KCNH2 Products)

Background: KV11.1, Potassium voltage-gated channel subfamily H member 2, Ether-a-go-go-related channel 1,The KV11.1 (HERG) channel is a member of the ether-a-go-go (EAG) subfamily of voltage-dependent K+ channels that includes the related proteins KV11.2 and KV11.3 (erg2 and erg3). KV11.1 possesses the signature structure of the voltage-dependent K+ channels: six membrane-spanning domains and intracellular N- and C-termini.The KV11.1 current is characterized by strong inward rectification with slow activation and very rapid inactivation kinetics. The channel is expressed in the brain and heart (where it underlies the IKr current) and has a central role in mediating repolarization of action potentials.1,2Mutations in the KV11.1 channel cause inherited long QT syndrome (LQTS) or abnormalities in the repolarization of the heart that are associated with life-threatening arrhythmias and sudden death. All the identified KV11.1 mutations produce loss of function of the channel via several cellular mechanisms ranging from alterations of gating properties, alterations of channel permeability/selectivity and alterations in intracellular channel trafficking that decreases the number of channels that reach the cell membrane.1,2 Recently, drug-induced forms of LQTS have been reported for a wide range of non-cardiac drugs including antihistamines, psychoactive agents and antimicrobials. All these drugs potently block the KV11.1 channel as an unintended side effect, prompting regulatory drug agencies to issue recommendations for the testing of new drugs for their potential KV11.1 blocking effect.In addition, KV11.1 expression was found to be upregulated in several tumor cell lines of different histogenesis, suggesting that it confers the cells some advantage in cell proliferation. Indeed, in several studies it has been shown that inhibition of the KV11.1 current leads to a decrease in tumor cell proliferation.3

Alternative names: KCNH2 (HERG), KV11.1, Potassium voltage-gated channel subfamily H member 2, Ether-a-go-go-related channel 1

Gene ID: 3757

NCBI Accession: NM_000238

UniProt: Q12809